Tuberculosis (TB) is an infection that can occur in every organ of the body, including the musculoskeletal system. Musculoskeletal involvement in TB can be missed because of its non-specific clinical signs. The disease may mimic inflammatory arthritis, and high clinical suspicion is required when dealing with longstanding swelling of soft tissues, bones, or joints. This is a case series consisting of four patients diagnosed with TB of the musculoskeletal system of the upper extremity and treated with anti-TB drugs over a period of three years. The aim was to analyze the usual presentation pattern, time delay in diagnosis, the key diagnostic tool, and mainstay treatment of choice. All four patients were treated with a regimen of a combination of anti-TB drugs, initial splinting, and intensive physiotherapy for functional rehabilitation and had complete resolution of pain and infection. The operative treatment was usually limited and mainly included debridement along with biopsy for definitive diagnosis. The mainstay treatment had been appropriate drug therapy. Musculoskeletal TB can be treated effectively with anti-TB drugs. Confirmation of the diagnosis with biopsy is vital in prompt initiation of the appropriate treatment, which can lead to better outcomes in patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471864 | PMC |
http://dx.doi.org/10.7759/cureus.69370 | DOI Listing |
ACS Infect Dis
January 2025
Infectious Diseases Division, CSIR─Indian Institute of Integrative Medicine, Jammu 180001, India.
Tuberculosis (TB), a leading infectious disease caused by the pathogen , poses a significant treatment challenge due to its unique characteristics and resistance to existing drugs. The conventional treatment regimens, which are lengthy and involve multiple drugs, often result in poor patient adherence and subsequent drug resistance, particularly with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. This highlights the urgent need for novel anti-TB therapies and new drug targets.
View Article and Find Full Text PDFMicroorganisms
December 2024
Bach Institute of Biochemistry, Fundamentals of Biotechnology, Federal Research Center, Russian Academy of Sciences, Moscow 119071, Russia.
(Mtb) is one of the most successful bacterial pathogens in human history. Even in the antibiotic era, Mtb is widespread and causes millions of new cases of tuberculosis each year. The ability to disrupt the host's innate and adaptive immunity, as well as natural persistence, complicates disease control.
View Article and Find Full Text PDFIntroduction: Tuberculosis (TB) poses a significant threat to global health, with millions of new infections and approximately one million deaths annually. Various modeling efforts have emerged, offering tailored data-driven and physiologically-based solutions for novel and historical compounds. However, this diverse modeling panorama may lack consistency, limiting result comparability.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Chinese Center for Disease Control and Prevention, National Tuberculosis Reference Laboratory, No. 155 Chang Bai Road, Changping District, Beijing, 102206, People's Republic of China.
Background: Diabetes mellitus (DM) is a major risk factor for tuberculosis (TB), However, limited research exists on their clinical and strain characteristics. This study aims to investigate the correlation between these factors in TB-DM patients in Changping District. METHODS: Whole genome sequencing (WGS) and drug susceptibility tests (DST) were performed on culture-positive strains.
View Article and Find Full Text PDFComput Biol Med
January 2025
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia; Drug Development Study Centre, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.
A higher death rate is associated with multiple factors, including medication resistance and co-infection with the human immunodeficiency virus (HIV). This shows the need to obtain new and effective drug candidates in improving tuberculosis (TB) treatment. In addition, the phosphatidylinositol mannosyltransferase (PimA) enzyme starts the production of phosphatidyl-myo-inositol.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!